Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Riederer

Showing results (91-100 of 244) with videos related to

Pageof 25
Sort By:
FEBS Letters|January 22, 2002
The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's diseaseLuigi Zecca, Ruggero Fariello, Peter Riederer, et al.
European Journal of Pharmacology|May 22, 2002
Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?Peter Riederer, Paul Foley, Gerhard Bringmann, et al.
International Review of Neurobiology|October 6, 2011
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's diseaseOrly Weinreb, Tamar Amit, Peter Riederer, et al.
Annals of the New York Academy of Sciences|April 24, 2004
The relevance of iron in the pathogenesis of Parkinson's diseaseMario E Götz, Kay Double, Manfred Gerlach, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|September 3, 2024
Therapeutic drug monitoring in Parkinson's diseaseThomas Müller, Manfred Gerlach, Gudrun Hefner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's diseaseManfred Gerlach, Gerd D Bartoszyk, Peter Riederer, et al.
Stress (Amsterdam, Netherlands)|November 26, 2009
Chronic exogenous corticosterone administration generates an insulin-resistant brain state in ratsJelena Osmanovic, Konstanze Plaschke, Melita Salkovic-Petrisic, et al.
Biomed Research International|June 17, 2015
Human Genetic DiseasesHao Deng, Peter Riederer, Han-Xiang Deng, et al.
Fortschritte Der Neurologie-Psychiatrie|May 13, 2020
[Structure and efferences of the substantia nigra pars compacta in Parkinson's disease]Peter Urban, Bjorn Falkenburger, Wolfgang H Jost, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 21, 2023
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerationsOnanong Phokaewvarangkul, Roongroj Bhidayasiri, Pedro Garcia-Ruiz, et al.
Pageof 25

Showing results (91-100 of 244) with videos related to

Sort By:
Pageof 25
FEBS Letters|January 22, 2002
The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's diseaseLuigi Zecca, Ruggero Fariello, Peter Riederer, et al.
European Journal of Pharmacology|May 22, 2002
Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?Peter Riederer, Paul Foley, Gerhard Bringmann, et al.
International Review of Neurobiology|October 6, 2011
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's diseaseOrly Weinreb, Tamar Amit, Peter Riederer, et al.
Annals of the New York Academy of Sciences|April 24, 2004
The relevance of iron in the pathogenesis of Parkinson's diseaseMario E Götz, Kay Double, Manfred Gerlach, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|September 3, 2024
Therapeutic drug monitoring in Parkinson's diseaseThomas Müller, Manfred Gerlach, Gudrun Hefner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 22, 2011
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's diseaseManfred Gerlach, Gerd D Bartoszyk, Peter Riederer, et al.
Stress (Amsterdam, Netherlands)|November 26, 2009
Chronic exogenous corticosterone administration generates an insulin-resistant brain state in ratsJelena Osmanovic, Konstanze Plaschke, Melita Salkovic-Petrisic, et al.
Biomed Research International|June 17, 2015
Human Genetic DiseasesHao Deng, Peter Riederer, Han-Xiang Deng, et al.
Fortschritte Der Neurologie-Psychiatrie|May 13, 2020
[Structure and efferences of the substantia nigra pars compacta in Parkinson's disease]Peter Urban, Bjorn Falkenburger, Wolfgang H Jost, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 21, 2023
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson's disease: clinical and therapeutic considerationsOnanong Phokaewvarangkul, Roongroj Bhidayasiri, Pedro Garcia-Ruiz, et al.
Pageof 25